Literature DB >> 31403861

Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.

Sara Bouberhan1, Eric Pujade-Lauraine2, Stephen A Cannistra1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31403861     DOI： 10.1200/JCO.19.00314

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

Review 1.  Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.

Authors:  Alexandra Lainé; Travis T Sims; Olivia Le Saux; Isabelle Ray-Coquard; Robert L Coleman
Journal:  Curr Oncol Rep       Date:  2021-11-09       Impact factor: 5.075

2.  Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.

Authors:  Rahul Majumdar; Shen Yin; Grace Moore; Simon N Powell; Atif J Khan; Nils Weinhold; Daniel S Higginson
Journal:  Mol Cancer Res       Date:  2022-07-06       Impact factor: 6.333

3.  Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study.

Authors:  Alessio Amatu; Gianluca Mauri; Federica Tosi; Katia Bencardino; Erica Bonazzina; Viviana Gori; Lorenzo Ruggieri; Sabrina Arena; Alberto Bardelli; Silvia Marsoni; Salvatore Siena; Andrea Sartore-Bianchi
Journal:  Cancers (Basel)       Date:  2022-02-25       Impact factor: 6.639

4.  LRH1 Promotes Tumor Cell Proliferation and Migration and Is Correlated With Poor Prognosis in Ovarian Cancer.

Authors:  Wenzhou Sun; Qingtao Shi; Jiaxin Li; Jinmeng Li; Libo Yu
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

5.  Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?

Authors:  Elena Fountzilas; Vassiliki Kotoula; Georgia-Angeliki Koliou; Michalis Liontos; Kyriaki Papadopoulou; Eleni Giannoulatou; Alexios Papanikolaou; Ioannis Tikas; Sofia Chrisafi; Davide Mauri; Kyriakos Chatzopoulos; Florentia Fostira; Dimitrios Pectasides; Georgios Oikonomopoulos; Dimitra Aivazi; Angeliki Andrikopoulou; Anastasios Visvikis; Gerasimos Aravantinos; Flora Zagouri; George Fountzilas
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

6.  Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.

Authors:  Andrew R Clamp; Domenica Lorusso; Amit M Oza; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; Terri Cameron; Sandra Goble; Robert L Coleman; Jonathan A Ledermann
Journal:  Int J Gynecol Cancer       Date:  2021-06-08       Impact factor: 4.661

7.  Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.

Authors:  Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew R Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; David Cella; Juliette Meunier; Sandra Goble; Terri Cameron; Lara Maloney; Ann-Christin Mörk; Josh Bedel; Jonathan A Ledermann; Robert L Coleman
Journal:  J Clin Oncol       Date:  2020-08-24       Impact factor: 44.544

8.  Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.

Authors:  Sweta Sharma Saha; Lucy Gentles; Alice Bradbury; Dominik Brecht; Rebecca Robinson; Rachel O'Donnell; Nicola J Curtin; Yvette Drew
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639

9.  Pharmacologic inhibition of Akt in combination with chemotherapeutic agents effectively induces apoptosis in ovarian and endometrial cancer cell lines.

Authors:  François Fabi; Pascal Adam; Sophie Parent; Laurence Tardif; Monique Cadrin; Eric Asselin
Journal:  Mol Oncol       Date:  2021-01-04       Impact factor: 6.603
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.